Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Gastrointestinal 1Breast 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cytarabine 899Cyclophosphamide 894fludarabine 517venetoclax 475fludarabine phosphate 464Azacitidine 452Rituximab 418Methotrexate 415Etoposide 319Filgrastim 299Busulfan 295Dexamethasone 285Vincristine 281Daunorubicin 280Peripheral Blood Stem Cell Transplantation 257Whole-Body Irradiation 240Mycophenolic Acid 231Decitabine 228Granulocyte Colony-Stimulating Factor 225Tacrolimus 219Idarubicin 203Melphalan 201Imatinib Mesylate 195Cyclosporine 182Doxorubicin 177Radiotherapy 169Prednisone 161Mitoxantrone 160Lenalidomide 159Mercaptopurine 155

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × crenigacestat × Other hematologic neoplasm × Clear all
NCT02518113 2019-09-11

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Eli Lilly and Company

Phase 1/2 Completed
36 enrolled 17 charts
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡